CD19 and neoplasm: CoCAR approaches are currently being developed for safe and enhanced targeting of hematologic malignancies by providing engineered co-stimulation upon recognition of lineage antigens CD19 or CD38, which are either co-expressed on the targeted tumor cells, or expressed on cells in the malignant bone marrow microenvironment [200,201].